Yoichi Takakusagi
Institute of Quantum Life Science
National Institutes for Quantum and Radiological Science and Technology
Yoichi Takakusagi is a senior scientist in National Institutes for Quantum and Radiological Science and Technology (QST) in Japan. He received his Ph.D. with honors from the Tokyo University of Science (TUS) in 2006.
During Dr. Takakusagi’s training and work as a Ph.D. student and an assistant professor in TUS, he conducted a drug screening from natural resources, and target protein exploration for bioactive small molecules of interest using the T7 phage display method. He also dedicated to the development of practical experimental techniques for drug target identification, such as biosensor-based high throughput biopanning.
He then moved to NCI/NIH as a visiting fellow (2011 to 2014) in Murali C. Cherukuri group. He joined their R&D of in vivo Electron Paramagnetic Resonance (EPR) oxygen imaging and hyperpolarized 13C magnetic resonance spectroscopic imaging (HP-MRSI) to study physiological and metabolic characteristics in tumors. He also investigated their applicability to evaluate the therapeutic response of tumors upon treatment with a hypoxia-activated prodrug, tumor radiosensitizer, and others.
After coming back to Japan as a research assistant professor at Kyushu University, he joined the JST/CREST research project of Molecular Technology (Dr. Sando’s team) for the development of brand-new hyperpolarized-NMR/MRI molecular probes and their biological application. Since 2017, he has been working at QST. His current research interest lies in the development and application of tumor diagnostics, therapeutics, and their combination (theranostics).
[Validation of small-molecule/protein interactions by the T7 phage display strategy using a quartz-crystal microbalance device].
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme Jul, 2009 | Pubmed ID: 19588885
Use of phage display technology for the determination of the targets for small-molecule therapeutics.
Expert opinion on drug discovery Apr, 2010 | Pubmed ID: 22823088
Multimodal biopanning of T7 phage-displayed peptides reveals angiomotin as a potential receptor of the anti-angiogenic macrolide Roxithromycin.
European journal of medicinal chemistry Jan, 2015 | Pubmed ID: 25528335
Direct Monitoring of γ-Glutamyl Transpeptidase Activity In Vivo Using a Hyperpolarized (13) C-Labeled Molecular Probe.
Angewandte Chemie (International ed. in English) 08, 2016 | Pubmed ID: 27483206
Hyperpolarized [1-C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer Predicts Efficacy of Targeting the Warburg Effect.
Clinical cancer research : an official journal of the American Association for Cancer Research 07, 2018 | Pubmed ID: 29599412
Intratumoral evaluation of 3D microvasculature and nanoparticle distribution using a gadolinium-dendron modified nano-liposomal contrast agent with magnetic resonance micro-imaging.
Nanomedicine : nanotechnology, biology, and medicine 06, 2018 | Pubmed ID: 29626524
Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice.
Cancer research 07, 2018 | Pubmed ID: 29792309
Using the QCM Biosensor-Based T7 Phage Display Combined with Bioinformatics Analysis for Target Identification of Bioactive Small Molecule.
Methods in molecular biology (Clifton, N.J.) , 2018 | Pubmed ID: 29846927
Design strategy for serine hydroxymethyltransferase probes based on retro-aldol-type reaction.
Nature communications 02, 2019 | Pubmed ID: 30787298
Design of Nuclear Magnetic Resonance Molecular Probes for Hyperpolarized Bioimaging.
Angewandte Chemie (International ed. in English) May, 2020 | Pubmed ID: 32372551
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有，本公司不涉及任何医疗业务和医疗服务。